INFLUENCE OF IMMUNOSUPPRESSIVE AND GENETICALLY ENGINEERED THERAPY WITH TNF –alpha INHIBITOR INFLIXIMAB ON MINERAL DENSITY OF BONE TISSUE IN PATIENTS WITH JUVENILE ARTHRITIS
Abstract
Key words: juvenile arthritis, mineral density of bone, osteoporosis, immunosuppressants, infliximab.
(Voprosy sovremennoi pediatrii — Current Pediatrics. – 2010;9(4):27-33)
About the Authors
A.O. LisitsynRussian Federation
E.I. Alexeeva
Russian Federation
S.I. Valieva
Russian Federation
T.M. Bzarova
Russian Federation
R.V. Denisova
Russian Federation
A.M. Chomakhidze
Russian Federation
K.B. Isaeva
Russian Federation
References
1. Алексеева Е.И., Литвицкий П.Ф. Ювенильный ревматоидный артрит: этиология, патогенез, клиника, алгоритмы диагностики и лечения. Под ред. А.А. Баранова. М.: Веди. 2007.
2. Cassidy J.T, R.E. Petty, R.M. Laxer, C.B. Lindsley Textbook of Pediatric Rheumatology 5th ed. Philadelphia: W.B. Saunders. 2005.
3. Prieur A.M., Chèdeville G. Prognostic factors in juvenile idiopathic arthritis. Curr. Rheumatol. Rep. 2001; 3(5): 371–378.
4. Thornton J., Ashcroft D., O'Neill T. et al. A systematic review of the effectiveness of strategies for reducing fracture risk in children with juvenile idiopathic arthritis with additional data on long-term risk of fracture and cost of disease management. Health Technol. Assess. 2008; 12 (3): 1–208.
5. French A.R., Mason T., Nelson A.M. et al. Osteopenia in adults with a history of juvenile rheumatoid arthritis. A population based study. J. Rheumatol. 2002; 29(5): 1065–1070.
6. Quarta L., Corrado A., Melillo N. et al. Juvenile idiopathic arthritis: an update on clinical and therapeutic approaches. Ann. Ital. Med. Int. 2005; 20 (4): 211–217.
7. Di Munno O., Delle Sedie A. Glucocorticoid - induced osteoporosis and rheumatic diseases. Pathogenesis, prevention and treatment. Reumatismo. 2006; 58(1): 11–21.
8. Feldmann M., Maini S. Role of cytokines in rheumatoid arthritis: an education in pathophysiology and therapeutics. Immunological Reviews. 2008; 223: 7–19
9. Гукасян Д.А., Балабанова Р.И., Смирнов А.В. Изучение взаимосвязи между минеральной плотностью костной ткани и клинико-лабораторными показателями активности ревматоидного артрита. Научно-практическая ревматология. 2005; 1: 18–21.
10. Mundy G.R. Osteoporosis and inflammation. Nutrition reviews. 2007; 65(12): 147–151
11. Насонов Е.Л., Гукасян Д.А., Насонова М.Б. Иммунопатология ревматоидного артрита и остеопороз: новые данные. Остеопороз и остеопатии. 2000. 2: 47.
12. Гукасян Д.А., Балабанова Р.И., Смирнов А.В. Изучение взаимосвязи между минеральной плотностью костной ткани и клинико-лабораторными показателями активности ревматоидного артрита. Научно-практическая ревматология. 2005; 1: 18–21.
13. Beutler B.A. The role of tumor necrosis factor in health and disease. J. Rheumatol. 1999; 26 (Suppl. 57): 16–21.
14. Dinarello C.A., Moldawer L.L. Proinflammatory and anti-inflammatory cytokines in rheumatoid arthritis. A primar for clinicians. Third edition. NY: Amgen Inc. 2002; 351.
15. Danks L., Sabokbar A., Gundle R., Athanasou N.A. Synovial macrophage-osteoclast differentiation in inflammatory arthritis. Ann. Rheum. Dis. 2002; 61: 916–921.
16. Насонов Е.Л. Фактор некроза опухоли–α – новая мишень для противовоспалительной терапии ревматоидного артрита. РМЖ. 2000; 17: 18–22.
17. Barksby H.E., Milner J.M., Patterson A.M. et al. Matrix metalloproteinase 10 promotion of collagenolysis via procollagenase activation: implications for cartilage degration in arthritis. Arthritis Rheum. 2006; 54: 3244–3253.
18. Rifas L. Bone and cytokines: beyond IL–1, IL–6 and TNF–ᾳ. Calcif. Tissue Int. 1999; 64: 1–7.
19. Chopin F., Garnero P., le Henanff A. et al. Long term effects of infliximab on bone and cartilage turnover markers in patients with rheumatoid arthritis. Ann. Rheum. Dis. 2008; 67(3): 353–357.
20. Haugeberg G., Conaghan P.G., Quinn M., Emery P. Bone loss in patients with active early rheumatoid arthritis: infliximab and methotrexate compared with methotrexate treatment alone. Explorative analysis from a 12 month randomised, double blind, placebo controlled study. Ann. Rheum. Dis. 2009; 68 (12): 1898–1901.
21. Visvanathan S., van der Heijde D., Deodhar A. et al. Effects of infliximab on markers of inflammation and bone turnover and associations with bone mineral density in patients with ankylosing spondylitis. Ann. Rheum. Dis. 2009; 68 (2): 175–182.
Review
For citations:
Lisitsyn A., Alexeeva E., Valieva S., Bzarova T., Denisova R., Chomakhidze A., Isaeva K. INFLUENCE OF IMMUNOSUPPRESSIVE AND GENETICALLY ENGINEERED THERAPY WITH TNF –alpha INHIBITOR INFLIXIMAB ON MINERAL DENSITY OF BONE TISSUE IN PATIENTS WITH JUVENILE ARTHRITIS. Current Pediatrics. 2010;9(4):27-33.
Email this article 
